Blurbs

Morgan Stanley Remains a Buy on RegenXBio (RGNX)

In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on RegenXBio (RGNXResearch Report), with a price target of $46.00. The company’s shares opened today at $34.88.

According to TipRanks, Purohit is an analyst with an average return of -17.6% and a 30.95% success rate. Purohit covers the Healthcare sector, focusing on stocks such as RegenXBio, Axsome Therapeutics, and Arcutis Biotherapeutics.

In addition to Morgan Stanley, RegenXBio also received a Buy from Berenberg Bank’s Caroline Palomeque in a report issued on August 4. However, on the same day, SVB Securities reiterated a Hold rating on RegenXBio (NASDAQ: RGNX).

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $46.46 and a one-year low of $18.69. Currently, RegenXBio has an average volume of 422.6K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Read More on RGNX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed